Malignant neoplasm of body of pancreas
ICD-10 C25.1 is a billable code used to indicate a diagnosis of malignant neoplasm of body of pancreas.
Malignant neoplasm of the body of the pancreas, commonly referred to as pancreatic cancer, is a highly aggressive form of cancer that originates in the pancreatic tissue. The pancreas is a vital organ involved in digestion and blood sugar regulation. The body of the pancreas is the central portion, and tumors in this area can lead to obstructive jaundice, weight loss, and abdominal pain. Staging pancreatic cancer is particularly challenging due to the lack of early symptoms and the tendency for the disease to be diagnosed at an advanced stage. The CA 19-9 tumor marker is often elevated in patients with pancreatic cancer and can be used to monitor treatment response, although it is not specific to the disease. The prognosis for patients diagnosed with malignant neoplasm of the body of the pancreas is generally poor, with a five-year survival rate of less than 10%, primarily due to late-stage diagnosis and aggressive tumor behavior. Treatment options may include surgical resection, chemotherapy, and radiation therapy, but the effectiveness is often limited by the cancer's advanced stage at diagnosis.
Detailed pathology reports, imaging studies, and treatment plans must be documented.
Patients presenting with jaundice, weight loss, or abdominal pain; follow-up after chemotherapy.
Ensure accurate staging and documentation of tumor markers for treatment planning.
Endoscopic reports, imaging studies, and biopsy results are critical.
Patients with obstructive jaundice or unexplained weight loss; evaluation of pancreatic masses.
Document the clinical rationale for imaging and biopsy to support coding.
Used for surgical resection of pancreatic tumors.
Operative reports detailing the procedure and findings.
Ensure that the surgical approach and tumor location are clearly documented.
CA 19-9 is a tumor marker that is often elevated in patients with pancreatic cancer. It is used to monitor treatment response and disease progression, although it is not specific to pancreatic cancer and can be elevated in other conditions.
